唑来膦酸应用于乳腺癌辅助治疗的研究

被引：2

作者：

李静平

刘运江

机构：

[1] 河北医科大学第四医院乳腺中心

来源：

临床外科杂志 | 2016年 / 24卷 / 03期

关键词：

唑来膦酸; 乳腺癌; 骨转移; 辅助治疗;

D O I：

暂无

中图分类号：

R737.9 [乳腺肿瘤];

学科分类号：

100214 [肿瘤学];

摘要：

唑来膦酸(zoledronic acid,ZOL)是第三代双膦酸盐(bisphosphonates,BPs)药物,通过抑制破骨细胞介导的骨重吸收作用,降低骨相关事件,预防肿瘤治疗相关骨流失,提高骨密度,是目前乳腺癌骨转移的标准治疗之一。越来越多临床前研究及临床研究结果表明,ZOL这种骨改良药物,不仅仅是一种骨保护剂,还具有直接和间接的抗肿瘤活性,可降低肿瘤复发、转移,改善预后。ZOL早期应用于乳腺癌辅助治疗的应用地位得以提高,尤其是对于低雌激素水平(自然或治疗相关性)的早期乳腺癌患者。

引用

页码：231 / 233

页数：3

共 12 条

[1]

Bisphosphonates, bone, and breast cancer recurrence [J].

Brufsky, Adam ;

Mathew, Aju .

LANCET, 2015, 386 (10001) :1319-1320

[2]

Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials [J].

Coleman, R. ;

Powles, T. ;

Paterson, A. ;

Gnant, M. ;

Anderson, S. ;

Diel, I. ;

Gralow, J. ;

von Minckwitz, G. ;

Moebus, V. ;

Bergh, J. ;

Pritchard, K. I. ;

Bliss, J. ;

Cameron, D. ;

Evans, V. ;

Pan, H. ;

Peto, R. ;

Bradley, R. ;

Gray, R. ;

Bartsch, R. ;

Dubsky, P. ;

Fesl, C. ;

Fohler, H. ;

Greil, R. ;

Jakesz, R. ;

Lang, A. ;

Luschin-Ebengreuth, G. ;

Marth, C. ;

Mlineritsch, B. ;

Samonigg, H. ;

Singer, C. F. ;

Steger, G. G. ;

Stoeger, H. ;

Olivotto, I. ;

Ragaz, J. ;

Christiansen, P. ;

Ejlertsen, B. ;

Ewertz, M. ;

Jensen, M-B ;

Moller, S. ;

Mouridsen, H. T. ;

Eiermann, W. ;

Hilfrich, J. ;

Jonat, W. ;

Kaufmann, M. ;

Kreienberg, R. ;

Schumacher, M. ;

Blohmer, J. U. ;

Costa, S. D. ;

Eidtmann, H. ;

Gerber, B. .

LANCET, 2015, 386 (10001) :1353-1361

[3]

Cancer Statistics, 2015 [J].

Siegel, Rebecca L. ;

Miller, Kimberly D. ;

Jemal, Ahmedin .

CA-A CANCER JOURNAL FOR CLINICIANS, 2015, 65 (01) :5-29

[4]

Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial [J].

Coleman, Robert ;

Cameron, David ;

Dodwell, David ;

Bell, Richard ;

Wilson, Caroline ;

Rathbone, Emma ;

Keane, Maccon ;

Gil, Miguel ;

Burkinshaw, Roger ;

Grieve, Robert ;

Barrett-Lee, Peter ;

Ritchie, Diana ;

Liversedge, Victoria ;

Hinsley, Samantha ;

Marshall, Helen .

LANCET ONCOLOGY, 2014, 15 (09) :997-1006

[5]

Zoledronic acid decreases gene expression of vascular endothelial growth factor and basic fibroblast growth factor by human epithelial cells [J].

Basso, Fernanda G. ;

Turrioni, Ana Paula S. ;

Hebling, Josimeri ;

de Souza Costa, Carlos Alberto .

BRITISH JOURNAL OF ORAL & MAXILLOFACIAL SURGERY, 2013, 51 (08) :971-973

[6]

Denosumab in breast cancer treatment [J].

Drooger, Jan C. ;

van der Padt, Annemieke ;

Sleijfer, Stefan ;

Jager, Agnes .

EUROPEAN JOURNAL OF PHARMACOLOGY, 2013, 717 (1-3) :12-19

[7]

Final 5-year results of Z-FAST trial [J].

Brufsky, Adam M. ;

Harker, W. Graydon ;

Beck, J. Thaddeus ;

Bosserman, Linda ;

Vogel, Charles ;

Seidler, Christopher ;

Jin, Lixian ;

Warsi, Ghulam ;

Argonza-Aviles, Eliza ;

Hohneker, John ;

Ericson, Solveig G. ;

Perez, Edith A. .

CANCER, 2012, 118 (05) :1192-1201

[8]

Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial [J].

Gnant, Michael ;

Mlineritsch, Brigitte ;

Stoeger, Herbert ;

Luschin-Ebengreuth, Gero ;

Heck, Dietmar ;

Menzel, Christian ;

Jakesz, Raimund ;

Seifert, Michael ;

Hubalek, Michael ;

Pristauz, Gunda ;

Bauernhofer, Thomas ;

Eidtmann, Holger ;

Eiermann, Wolfgang ;

Steger, Guenther ;

Kwasny, Werner ;

Dubsky, Peter ;

Hochreiner, Gerhard ;

Forsthuber, Ernst-Pius ;

Fesl, Christian ;

Greil, Richard .

LANCET ONCOLOGY, 2011, 12 (07) :631-641

[9]

Tumor Metastasis: Molecular Insights and Evolving Paradigms [J].

Valastyan, Scott ;

Weinberg, Robert A. .

CELL, 2011, 147 (02) :275-292

[10]

Cost-Effectiveness of Zoledronic Acid Plus Endocrine Therapy in Premenopausal Women With Hormone-Responsive Early Breast Cancer [J].

Delea, Thomas E. ;

Taneja, Charu ;

Sofrygin, Oleg ;

Kaura, Satyin ;

Gnant, Michael .

CLINICAL BREAST CANCER, 2010, 10 (04) :267-274

← 1 2 →